Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06535399 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT06535399 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 29 participants.
The verdict
NCT06535399, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Interventions
- DRUG BMS-986369
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06535399
The ClinicalTrials.gov registry entry for NCT06535399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986369 is the first listed.
NCT06535399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06535399 about?
NCT06535399 is a clinical study titled "Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment". The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
What is the current status of trial NCT06535399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2024-08-15. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT06535399?
The interventions under investigation include: BMS-986369 (DRUG).
Who is sponsoring clinical trial NCT06535399?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.